{"title":"RNA methylation: A potential therapeutic target in autoimmune disease.","authors":"Lele Li, Xiaoping Xia, Tian Yang, Yuchao Sun, Xueke Liu, Wei Xu, Mei Lu, Dawei Cui, Yingping Wu","doi":"10.1080/08830185.2023.2280544","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) are caused by the body's immune response to autoantigens. The pathogenesis of autoimmune diseases is unclear. Numerous studies have demonstrated that RNA methylation plays a key role in disease progression, which is essential for post-transcriptional regulation and has gradually become a broad regulatory mechanism that controls gene expression in various physiological processes, including RNA nuclear output, translation, splicing, and noncoding RNA processing. Here, we outline the writers, erasers, and readers of RNA methylation, including N6-methyladenosine (m<sup>6</sup>A), 2'-O-methylation (Nm), 2'-O-dimethyladenosine (m<sup>6</sup>Am), N1-methyladenosine (m<sup>1</sup>A), 5-methylcytidine (m<sup>5</sup>C) and N7-methylguanosine (m<sup>7</sup>G). As the role of RNA methylation modifications in the immune system and diseases is explained, the potential treatment value of these modifications has also been demonstrated. This review reports the relationship between RNA methylation and autoimmune diseases, highlighting the need for future research into the therapeutic potential of RNA modifications.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2023.2280544","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) are caused by the body's immune response to autoantigens. The pathogenesis of autoimmune diseases is unclear. Numerous studies have demonstrated that RNA methylation plays a key role in disease progression, which is essential for post-transcriptional regulation and has gradually become a broad regulatory mechanism that controls gene expression in various physiological processes, including RNA nuclear output, translation, splicing, and noncoding RNA processing. Here, we outline the writers, erasers, and readers of RNA methylation, including N6-methyladenosine (m6A), 2'-O-methylation (Nm), 2'-O-dimethyladenosine (m6Am), N1-methyladenosine (m1A), 5-methylcytidine (m5C) and N7-methylguanosine (m7G). As the role of RNA methylation modifications in the immune system and diseases is explained, the potential treatment value of these modifications has also been demonstrated. This review reports the relationship between RNA methylation and autoimmune diseases, highlighting the need for future research into the therapeutic potential of RNA modifications.
自身免疫性疾病如类风湿关节炎(RA)、系统性红斑狼疮(SLE)和炎症性肠病(IBD)是由机体对自身抗原的免疫反应引起的。自身免疫性疾病的发病机制尚不清楚。大量研究表明,RNA甲基化在疾病进展中起着关键作用,对转录后调控至关重要,并逐渐成为控制RNA核输出、翻译、剪接、非编码RNA加工等多种生理过程中基因表达的广泛调控机制。在这里,我们概述了RNA甲基化的书写器、擦除器和读取器,包括n6 -甲基腺苷(m6A)、2'- o -甲基化(Nm)、2'- o -二甲基腺苷(m6Am)、n1 -甲基腺苷(m1A)、5-甲基胞苷(m5C)和n7 -甲基鸟苷(m7G)。随着RNA甲基化修饰在免疫系统和疾病中的作用被解释,这些修饰的潜在治疗价值也被证明。这篇综述报道了RNA甲基化与自身免疫性疾病之间的关系,强调了未来研究RNA修饰治疗潜力的必要性。
期刊介绍:
This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles.
This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders.
Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).